YMAB Y-mAbs Therapeutics Inc.

28.88
-0.57  -2%
Previous Close 29.45
Open 29.45
Price To Book 10.58
Market Cap 1,147,356,654
Shares 39,728,416
Volume 335,030
Short Ratio
Av. Daily Volume 244,144
Stock charts supplied by TradingView

NewsSee all news

  1. Y-mAbs Announces Update on Omburtamab in DSRCT

    NEW YORK, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  2. Y-mAbs Announces Third Quarter 2019 Financial Results and Recent Corporate Developments

    NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel,

  3. Y-mAbs to Announce Third Quarter 2019 Financial and Operating Results on November 13

    NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its third quarter 2019 financial and operating results on Wednesday,

  4. Y-mAbs Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

    NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  5. Y-mAbs Announces Naxitamab Update

    NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (NASDAQ:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Rolling BLA filing to commence November 2019 and to be completed by 1Q 2020.
Naxitamab
Relapsed/Refractory High-Risk Neuroblastoma
BLA filing due 1Q 2020.
Omburtamab
CNS/Leptomeningeal Metastases from Neuroblastoma

Latest News

  1. Y-mAbs Announces Update on Omburtamab in DSRCT

    NEW YORK, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  2. Y-mAbs Announces Third Quarter 2019 Financial Results and Recent Corporate Developments

    NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel,

  3. Y-mAbs to Announce Third Quarter 2019 Financial and Operating Results on November 13

    NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its third quarter 2019 financial and operating results on Wednesday,

  4. Y-mAbs Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

    NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  5. Y-mAbs Announces Naxitamab Update

    NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (NASDAQ:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel,

  6. Velan Launches Consent Solicitation to Reconstitute the Progenics Board With Its Five Highly-Qualified, Independent Director Nominees

    Believes its Five Completely Independent Nominees Would Bring Much-Needed Skill Sets and Drastically Improve the Board's Strategic Oversight and Corporate Governance Failings Expresses Disappointment with Current